СОВРЕМЕННЫЕ МЕТОДЫ ИММУНОАНАЛИЗА ДЛЯ ВЫЯВЛЕНИЯ БИОМАРКЕРОВ РЕВМАТОИДНОГО АРТРИТА

Ревматоидный артрит (РА) является хроническим аутоиммунным заболеванием с высокой инвалидизирующей способностью, ранняя диагностика которого имеет ключевое значение для своевременного назначения базисных противоревматических препаратов и улучшения прогноза. В последние десятилетия особое внимание уделяется серологическим биомаркерам, среди которых ведущую роль играют ревматоидный фактор (РФ) и антитела к цитруллинированным белкам (АЦБ), включая анти-CCP (англ. anti-cyclic citrullinated peptide antibodies, антитела к циклическому цитруллинированному пептиду) и анти-MCV (англ. anti-mutated citrullinated vimentin antibodies, антитела к мутантному цитруллинированному виментину). Эти маркеры позволяют не только подтвердить диагноз, но и прогнозировать риск агрессивного течения и эрозивных изменений суставов. Современные методы иммуноанализа существенно расширили диагностические возможности. Наряду с традиционными подходами (латекс-агглютинация, иммуноферментный анализ (ИФА), турбидиметрия) активно внедряются инновационные технологии: электрохимическая импедансная спектроскопия, спектроскопия комбинационного рассеяния с усилением поверхности (SERS), фотоэлектрические сенсоры и микрожидкостные платформы. Особое значение имеют мультиплексные иммуноанализы, обеспечивающие одновременное выявление нескольких биомаркеров в одном образце, что повышает точность диагностики, облегчает стратификацию пациентов и способствует реализации принципов персонализированной медицины. Несмотря на очевидные преимущества, мультиплексные методы сталкиваются с рядом ограничений: необходимостью использования высокоспецифичных антител, риском перекрёстной реактивности, отсутствием унифицированных эталонных стандартов для АЦБ, а также сложностями в обеспечении контроля качества. Дальнейшее развитие технологий связано с стандартизацией анализов, внедрением международных контрольных материалов и оптимизацией диагностических порогов. Таким образом, интеграция современных методов иммуноанализа и мультиплексных платформ в клиническую практику открывает новые возможности для ранней диагностики и прогнозирования РА, что в конечном итоге может снизить частоту инвалидизации и улучшить качество жизни пациентов.

1. Насонов Е.Л., Авдеева А.С., Дибров Д.А. Ревматоидный артрит как клинико-иммунологический синдром: фокус на серонегативный субтип заболевания. Научно-практическая ревматология. 2023; 61(3): 276-291.

2. Щендригин И.Н., Мажаров В.Н. Профиль коморбидных состояний и структура смертности пациентов с ревматоидным артритом в Ставропольском крае: предварительные результаты. Медицинский вестник Юга России. 2022; 13(3): 173-182.

3. Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity. 2022; 55(12): 2255-2270. Doi: 10.1016/j.immuni.2022.11.009.

4. Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023 Nov 25; 402(10416): 2019-2033. Doi: 10.1016/S0140-6736(23)01525-8.

5. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018; 320(13): 1360-1372. Doi: 10.1001/jama.2018.13103.

6. Salaffi F, Carotti M, Di Carlo M, et al. Resonance Imaging (MRI)-Based Semi-Quantitative Methods for Rheumatoid Arthritis: From Scoring to Measurement. J Clin Med. 2024 Jul 16; 13(14): 4137. Doi: 10.3390/jcm13144137.

7. van Delft MAM, Huizinga TWJ. An overview of autoantibodies in rheumatoid arthritis. J Autoimmun. 2020; 110: 102392. Doi: 10.1016/j. jaut.2019.102392.

8. Steiner G, Toes REM. Autoantibodies in rheumatoid arthritis — rheumatoid factor, anticitrullinated protein antibodies and beyond. Curr Opin Rheumatol. 2024; 36(3): 217-224. Doi: 10.1097/BOR.0000000000001006.

9. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9): 2569-81. Doi: 10.1002/art.27584.

10. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Ревматоидный артрит. — М., 2024. URL: https://cr.minzdrav.gov.ru/view-cr/250_3

11. Neto M, Mendes B, Albuquerque F, da Silva JAP. Novel biomarkers in RA: Implication for diagnosis, prognosis, and ethacrylate treatment. Best Pract Res Clin Rheumatol. 2025; 39(1): 102021. Doi: 10.1016/j.berh.2024.102021.

12. Wu CY, Yang HY, Luo SF, Lai JH. From Rheumatoid Factor to Anti-Citrullinated Protein Antibodies and Anti-Carbamylated Protein Antibodies for Diagnosis and Prognosis Prediction in Patients with Rheumatoid Arthritis. Int J Mol Sci. 2021; 22(2): 686. Doi: 10.3390/ijms22020686.

13. Гуляев СВ, Стрижаков ЛА, Моисеев СВ. Ревматоидный фактор: история изучения и эволюция представлений. Терапевтический архив. 2023; 95(5): 444-446.

14. PIKE RM, SULKIN SE, COGGESHALL HC. Concerning the nature of the factor in rheumatoid-arthritis serum responsible for increased agglutination of sensitized sheep erythrocytes. J Immunol. 1949 Dec; 63(4): 447-63.

15. Rönnelid J, Turesson C, Kastbom A. Autoantibodies in Rheumatoid Arthritis — Laboratory and Clinical Perspectives. Front Immunol. 2021; 12: 685312. Doi: 10.3389/fimmu.2021.685312.

16. Motta F, Bizzaro N, Giavarina D, et al. Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis. RMD Open. 2023 Aug; 9(3): e002817. Doi: 10.1136/rmdopen-2022-002817.

17. Sieghart D, Platzer A, Studenic P, et al. Determination of Autoantibody Isotypes Increases the Sensitivity of Serodiagnostics in Rheumatoid Arthritis. Front Immunol. 2018; 9: 876. Doi: 10.3389/fimmu.2018.00876.

18. Hermosillo-Villafranca JA, Guillén-Lozoya AH, Vega-Morales D, et al. Role of rheumatoid factor isotypes and anti-citrullinated peptide antibodies in the differential diagnosis of non-selected patients with inflammatory arthralgia. Reumatol Clin (Engl Ed). 2021; 17(1): 12-15. English, Spanish. Doi: 10.1016/j.reuma.2019.03.001.

19. Sokolova MV, Schett G, Steffen U. Autoantibodies in Rheumatoid Arthritis: Historical Background and Novel Findings. Clin Rev Allergy Immunol. 2022; 63(2): 138-151. Doi: 10.1007/s12016-021-08890-1.

20. Sokolove J, Johnson DS, Lahey LJ, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014; 66(4): 813-21. Doi: 10.1002/art.38307.

21. Pertsinidou E, Saevarsdottir S, Manivel VA, et al. In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation. Ann Rheum Dis. 2024; 83(3): 277-287. Doi: 10.1136/ard-2023-224728.

22. Lingampalli N, Sokolove J, Lahey LJ, et al. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis. Clin Immunol. 2018; 195: 119-126. Doi: 10.1016/j.clim.2018.05.004.

23. Lingampalli N, Sokolove J, Lahey LJ, et al. Combination of anti-citrullinated protein antibodies and rheumatoid factor is associated with increased systemic inflammatory mediators and more rapid progression from preclinical to clinical rheumatoid arthritis. Clin Immunol. 2018; 195: 119-126. Doi: 10.1016/j.clim.2018.05.004.

24. Curran AM, Naik P, Giles JT, Darrah E. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets. Nat Rev Rheumatol. 2020; 16(6): 301-315. Doi: 10.1038/s41584-020-0409-1.

25. Liu J, Gao J, Wu Z, et al. Anti-citrullinated Protein Antibody Generation, Pathogenesis, Clinical Application, and Prospects. Front Med (Lausanne). 2022; 8: 802934. Doi: 10.3389/fmed.2021.802934.

26. Iyengar KP, Vaish A, Nune A. Anti-cyclic citrullinated peptide antibody (ACPA) and Rheumatoid arthritis: Clinical relevance. J Clin Orthop Trauma. 2021; 24: 101729. Doi: 10.1016/j.jcot.2021.101729.

27. Nienhuis RL, Mandema E. A NEW SERUM FACTOR IN PATIENTS WITH RHEUMATOID ARTHRITIS; THE ANTIPERINUCLEAR FACTOR. Ann Rheum Dis. 1964 ;23(4): 302-5. Doi: 10.1136/ard.23.4.302

28. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br Med J. 1979; 2(6182): 97-9. Doi: 10.1136/bmj.2.6182.97.

29. Sebbag M, Simon M, Vincent C, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995; 95(6): 2672-9. Doi: 10.1172/JCI117969.

30. Abedian Z, Sagafi M, Kenari SA, Abedian F. Anti-perinuclear Factor as Diagnostic Marker in Rheumatoid Arthritis. J Clin Diagn Res. 2015; 9(9): OC13-6. Doi: 10.7860/JCDR/2015/14962.6456.

31. Sun P, Wang W, Chen L, et al. Diagnostic value of autoantibodies combined detection for rheumatoid arthritis. J Clin Lab Anal. 2017; 31(5): e22086. Doi: 10.1002/jcla.22086.

32. Wang XP, Cheng QY, Gu MM, et al. Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: a meta-analysis. Clin Rheumatol. 2019; 38(7): 1841-1849. Doi: 10.1007/s10067-019-04464-x.

33. Schellekens GA, Visser H, de Jong BA, et al.The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000; 43(1): 155-63. Doi: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3.

34. Meyer PW, Ally MM, Anderson R. Reliable and cost-effective serodiagnosis of rheumatoid arthritis. Rheumatol Int. 2016; 36(6): 751-8. Doi: 10.1007/s00296-016-3433-3.

35. Ji M, Hur M, Moon HW, et al. Comparison of second-and third-generation immunoassays for detection of anti-cyclic citrullinated peptide antibodies. Scand J Clin Lab Invest. 2018; 78(6): 477-482. Doi: 10.108 0/00365513.2018.1499957.

36. Di Matteo A, Mankia K, Duquenne L, et al. Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid Arthritis. Arthritis Rheumatol. 2020; 72(11): 1820-1828. Doi: 10.1002/art.41402.

37. Vos I, Van Mol C, Trouw LA, et al. Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. Clin Rheumatol. 2017; 36(7): 1487-1492. Doi: 10.1007/s10067-017-3684-8.

38. D’Onofrio B, Selmi C, Gremese E. Are seronegative patients with rheumatoid arthritis and clinically suspect arthralgia properly represented in randomized clinical trials? Clin Rheumatol. 2025; 44(1): 515-519. Doi: 10.1007/s10067-024-07187-w.

39. Szekanecz Z, Szabó Z, Zeher M, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factornegative RA population. Immunol Res. 2013; 56(2-3): 439-43. Doi: 10.1007/s12026-013-8425-8.

40. Sieghart D, Konrad C, Swiniarski S, et al. The diagnostic and prognostic value of IgG and IgA anti-citrullinated protein antibodies in patients with early rheumatoid arthritis. Front Immunol. 2023; 13: 1096866. Doi: 10.3389/fimmu.2022.1096866.

41. Nelson HA, Banerjee D, Novis CL, et al. A comparison of anti-cyclic citrullinated peptides (CCP3 and CCP3.1) autoantibody tests in rheumatoid arthritis. Pract Lab Med. 2024; 41: e00420. Doi: 10.1016/j.plabm.2024.e00420

42. Paulin D, Lilienbaum A, Kardjian S, et al. Vimentin: Regulation and pathogenesis. Biochimie. 2022; 197: 96-112. Doi: 10.1016/j. biochi.2022.02.003

43. Lee YH, Bae SC, Song GG. Diagnostic accuracy of anti-MCV and anti-CCP antibodies in rheumatoid arthritis: A meta-analysis. Z Rheumatol. 2015; 74(10): 911-8. Doi: 10.1007/s00393-015-1598-x.

44. Ebrahimi-Rad M, Khatami S, Akhbari H, et al. Evaluation of autoantibodies against vimentin and α-enolase in rheumatoid arthritis patients. Reumatologia. 2020; 58(6): 350-356. Doi: 10.5114/reum.2020.101276

45. Nelson HA, Martins TB, Saadalla A, Nandakumar V. Evaluation of the clinical performance of anti-mutated citrullinated vimentin antibody and 14-3-3 eta testing in rheumatoid arthritis. Clin Chem Lab Med. 2024; 63(4): 790-796. Doi: 10.1515/cclm-2024-1112.

46. Hagras A, Mohasseb D, Taleb R, et al. Clinical significance of antimutated citrullinated vimentin antibodies in rheumatoid arthritis patients. Hum Antibodies. 2024; 32(2): 75-83. Doi: 10.3233/HAB-240007.

47. Trier NH, Houen G. Anti-citrullinated protein antibodies as biomarkers in rheumatoid arthritis. Expert Rev Mol Diagn. 2023; 23(10): 895-911. Doi: 10.1080/14737159.2023.2247986

48. Falkenburg WJJ, von Richthofen HJ, Koers J, et al. Clinically relevant discrepancies between different rheumatoid factor assays. Clin Chem Lab Med. 2018; 56(10): 1749-1758. Doi: 10.1515/cclm-2017-0988.

49. Van Hoovels L, Jacobs J, Vander Cruyssen B, et al. Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis. Ann Rheum Dis. 2018; 77(5): 667-677. Doi: 10.1136/annrheumdis-2017-212365.

50. Shapiro SC. Biomarkers in Rheumatoid Arthritis. Cureus. 2021; 13(5): e15063. Doi: 10.7759/cureus.15063.

51. Oskam N, Ooijevaar-de Heer P, Kos D, et al. Next-generation rheumatoid factor assay provides improved predictive power for the development of arthritis in patients at risk. RMD Open. 2024; 10(3): e004172. Doi: 10.1136/rmdopen-2024-004172.

52. Yang X, Cai Y, Xue B, Zhang B. Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis. J Int Med Res. 2021; 49(9): 3000605211047714. Doi: 10.1177/03000605211047714.

53. Martinez-Prat L, Nissen MJ, Lamacchia C, et al. Comparison of Serological Biomarkers in Rheumatoid Arthritis and Their Combination to Improve Diagnostic Performance. Front Immunol. 2018; 9: 1113. Doi: 10.3389/fimmu.2018.01113.

54. Pope JE, Movahedi M, Rampakakis E, et al. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). RMD Open. 2018; 4(2): e000738. Doi: 10.1136/rmdopen-2018-000738.

55. Chinnadayyala SR, Park J, Abbasi MA, Cho S. Label-free electrochemical impedimetric immunosensor for sensitive detection of IgM rheumatoid factor in human serum. Biosens Bioelectron. 2019; 143: 111642. Doi: 10.1016/j.bios.2019.111642.

56. Veigas B, Matias A, Calmeiro T, et al. Antibody modified gold nanoparticles for fast colorimetric screening of rheumatoid arthritis. Analyst. 2019; 144(11): 3613-3619. Doi: 10.1039/c9an00319c.

57. Schmidt C, Borcherding H, Thiele T, et al. Fluorescence-encoded poly(methyl ethacrylate) nanoparticles for a lateral flow assay detecting IgM autoantibodies in rheumatoid arthritis. Anal Biochem. 2021; 633: 114389. Doi: 10.1016/j.ab.2021.114389.

58. Cho J, Pyo JY, Fadriquela A, et al. Comparison of the analytical and clinical performances of four anti-cyclic citrullinated peptide antibody assays for diagnosing rheumatoid arthritis. Clin Rheumatol. 2021; 40(2): 565-573. Doi: 10.1007/s10067-020-05412-w

59. Chinnadayyala SR, Cho S. Electrochemical Immunosensor for the Early Detection of Rheumatoid Arthritis Biomarker: Anti-Cyclic Citrullinated Peptide Antibody in Human Serum Based on Avidin-Biotin System. Sensors (Basel). 2020; 21(1): 124. Doi: 10.3390/s21010124.

60. Selvam S.P., Chinnadayyala S.R., Cho S. Electrochemical nanobiosensor for early detection of rheumatoid arthritis biomarker: Anti-cyclic citrullinated peptide antibodies based on polyaniline (PANI)/MoS2-modified screen-printed electrode with PANI-Au nanomatrix-based signal amplification Sens. Actuators B Chem. 2021; 333 (2021). Doi: 10.1016/j.snb.2021.129570

61. Vu TT, Song S, Lai HD, et al. Coverage degrees of colloids on electrochemical electrodes and signal amplification for anti-citrullinated peptide antibody detection Sens. Bio-Sens. Res. 2020 27 (2020). Doi: 10.1016/j.sbsr.2020.100322

62. Lin CY, Nhat Nguyen UT, Hsieh HY, et al. Peptide-based electrochemical sensor with nanogold enhancement for detecting rheumatoid arthritis. Talanta. 2022; 236: 122886. Doi: 10.1016/j. talanta.2021.122886.

63. Chen HM, Tsai YH, Hsu CY, et al. Peptide-Coated Bacteriorhodopsin-Based Photoelectric Biosensor for Detecting Rheumatoid Arthritis. Biosensors (Basel). 2023; 13(10): 929. Doi: 10.3390/bios13100929.

64. Szarka E, Aradi P, Huber K, et al. Affinity Purification and Comparative Biosensor Analysis of Citrulline-Peptide-Specific Antibodies in Rheumatoid Arthritis. Int J Mol Sci. 2018; 19(1): 326. Doi: 10.3390/ijms19010326.

65. Abd Elkodous M, El-Sayyad GS, Abdelrahman IY, et al. Therapeutic and diagnostic potential of nanomaterials for enhanced biomedical applications. Colloids Surf B Biointerfaces. 2019; 180: 411-428. Doi: 10.1016/j.colsurfb.2019.05.008.

66. Zhao Y, Liu Y, Li X, et al. Label-free ECL immunosensor for the early diagnosis of rheumatoid arthritis based on asymmetric heterogeneous polyaniline-gold nanomaterial. Sens. Actuators B Chem. 2018; 257 (2018): 354-361.

67. Hwang EY, Lee JH, Lim DW. Anisotropic Bimetallic Core-Satellite-Poly(aniline) Nanohybrids for Detection of Autoantibodies. Macromol Rapid Commun. 2020; 41(20): e2000331. Doi: 10.1002/marc.202000331.

68. Ramos KC, Macías MDPC. Microdevice immunoassay with conjugated magnetic nanoparticles for rapid anti-cyclic citrullinated peptide (anti-CCP) detection. Talanta. 2021; 224: 121801. Doi: 10.1016/j.talanta.2020.121801.

69. Deng X, Zeng M, Wang X, et al. Preparation and characterization of cyclic citrullinated peptide-immobilized latex beads for measurement of anti-citrillinated protein antibody through latex particle-enhanced turbidimetric immunoassay. J Chromatogr A. 2021; 1642: 462000. Doi: 10.1016/j.chroma.2021.462000

70. Sheng H, Hu ZG, Liu J, et al. Determination of Anticyclic Citrullinated Peptide Based on Biotin-Streptavidin-Amplified Time-Resolved Fluoroimmunoassay. J Clin Lab Anal. 2015; 29(6): 474-9. Doi: 10.1002/jcla.21796

71. Tai WY, Chen TL, Wang HM, Fu LM. Rapid Microfluidic Biosensor for Point-of-Care Determination of Rheumatoid Arthritis via Anti-Cyclic Citrullinated Peptide Antibody Detection. Biosensors (Basel). 2024; 14(11): 545. Doi: 10.3390/bios14110545.

72. Vanova V, Mitrevska K, Milosavljevic V, et al. Peptide-based electrochemical biosensors utilized for protein detection. Biosens Bioelectron. 2021; 180: 113087. Doi: 10.1016/j.bios.2021.113087.

73. Angela S, Fadhilah G, Hsiao WW, et al. Nanomaterials in the treatment and diagnosis of rheumatoid arthritis: Advanced approaches. SLAS Technol. 2024; 29(4): 100146. Doi: 10.1016/j.slast.2024.100146.

74. Karachaliou CE, Livaniou E. Immunosensors for Autoimmune-Disease-Related Biomarkers: A Literature Review. Sensors (Basel). 2023; 23(15): 6770. Doi: 10.3390/s23156770.

75. Guerrero S, Sánchez-Tirado E, Martínez-García G, et al. Electrochemical biosensor for the simultaneous determination of rheumatoid factor and anti-cyclic citrullinated peptide antibodies in human serum. Analyst. 2020; 145(13): 4680-4687. doi: 10.1039/d0an00481b.

76. Sánchez-Tirado E, Agüí L, Sánchez-Paniagua M, González-Cortés A, et al. Serum Autoantibody Biomarkers for Management of Rheumatoid Arthritis Disease. Biosensors (Basel). 2023; 13(3): 381. doi: 10.3390/bios13030381.

77. Angela S, Fadhilah G, Hsiao WW, et al. Nanomaterials in the treatment and diagnosis of rheumatoid arthritis: Advanced approaches. SLAS Technol. 2024; 29(4): 100146. doi: 10.1016/j.slast.2024.100146.

78. Hwang EY, Lee JH, Lim DW. Directional self-assembly of anisotropic bimetal-poly(aniline) nanostructures for rheumatoid arthritis diagnosis in multiplexing. Anal Chim Acta. 2021; 1174: 338699. doi: 10.1016/j.aca.2021.338699

79. Wu TH, Tsai YC, Kuo FC, et al. A microfluidic platform for detection and quantification of two biomarkers for rheumatoid arthritis. Sens. Actuators B Chem. 2023; 383 (2023). Doi: 10.1016/j.snb.2023.133587

80. García-Moreno C, Gómara MJ, Bleda MJ, et al. Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis. PLoS One. 2019; 14(5): e0215927. doi: 10.1371/journal.pone.0215927.

81. Chen KY, Tsai YC, Kuo FC, et al. A portable optical detection system for rapid quantification of two rheumatoid arthritis biomarkers. Anal Chim Acta. 2025; 1336: 343493. doi: 10.1016/j.aca.2024.343493.

82. Renger F, Bang H, Feist E, et al. Immediate determination of ACPA and rheumatoid factor--a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther. 2010; 12(3): R120. doi: 10.1186/ar3057.

83. Zandman-Goddard G, Soriano A, Gilburd B, et al. A novel bedside test for ACPA: the CCPoint test is moving the laboratory to the rheumatologist’s office. Immunol Res. 2017; 65(1): 363-368. doi: 10.1007/s12026-016-8846-2.

84. Laborde CM, Castro-Santos P, Díaz-Peña R. Contribution of Multiplex Immunoassays to Rheumatoid Arthritis Management: From Biomarker Discovery to Personalized Medicine. J Pers Med. 2020; 10(4): 202. doi: 10.3390/jpm10040202.

85. Todd DJ, Knowlton N, Amato M, et al. Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis Rheum. 2011; 63(4): 894-903. doi: 10.1002/art.30213

86. van Heemst J, Trouw LA, Nogueira L, et al. An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. Arthritis Res Ther. 2015; 17: 276. doi: 10.1186/s13075-015-0786-z.

87. Tighe PJ, Ryder RR, Todd I, Fairclough LC. ELISA in the multiplex era: potentials and pitfalls. Proteomics Clin Appl. 2015; 9(3-4): 406-22. doi: 10.1002/prca.201400130.

88. Savvateeva E, Smoldovskaya O, Feyzkhanova G, et al. Multiple biomarker approach for the diagnosis and therapy of rheumatoid arthritis. Crit Rev Clin Lab Sci. 2021; 58(1): 17-28. doi: 10.1080/10408363.2020.1775545.

89. Jacobs JFM, Bossuyt X. Standardization and harmonization of autoimmune diagnostics. Clin Chem Lab Med. 2018; 56(10): 1563-1567. doi: 10.1515/cclm-2018-0807.

90. Van Hoovels L, Studenic P, Sieghart D, et al. Impact of autoimmune serology test results on RA classification and diagnosis. J Transl Autoimmun. 2022; 5: 100142. doi: 10.1016/j.jtauto.2022.100142

91. Bizzaro N, Pregnolato F, van Boekel MA, et al. Preliminary evaluation of the first international reference preparation for anticitrullinated peptide antibodies. Ann Rheum Dis. 2012; 71(8): 1388-92. doi: 10.1136/annrheumdis-2011-200693.

92. Van Hoovels L, Studholme L, Vander Cruyssen B, et al. Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Ann Rheum Dis. 2022; 81(10): 1379-1384. doi: 10.1136/annrheumdis-2021-221849.

93. Monogioudi E, Martos G, Hutu DP, et al. Standardization of autoimmune testing — is it feasible? Clin Chem Lab Med. 2018; 56(10): 1734-1742. doi: 10.1515/cclm-2017-1077.

94. Pineda-Sic RA, Vega-Morales D, Santoyo-Fexas L, et al. Are the cutoffs of the rheumatoid factor and anti-cyclic citrullinated peptide antibody different to distinguish rheumatoid arthritis from their primary differential diagnoses? Int J Immunogenet. 2024; 51(1): 1-9. doi: 10.1111/iji.12643.

95. Fierz W, Bossuyt X. Likelihood Ratios as Value Proposition for Diagnostic Laboratory Tests. J Appl Lab Med. 2020; 5(5): 1061-1069. doi: 10.1093/jalm/jfaa064.

96. Fierz W, Bossuyt X. Likelihood Ratio Approach and Clinical Interpretation of Laboratory Tests. Front Immunol. 2021; 12: 655262. doi: 10.3389/fimmu.2021.655262.

97. Vandebeek D, Lodewijckx E, Van Hoovels L, et al. Integrating pretest probability for rheumatoid arthritis with likelihood ratios of RF and ACPA to improve clinical utility of rheumatoid arthritis autoantibody testing. Clin Chim Acta. 2025; 564: 119928. doi: 10.1016/j.cca.2024.119928.

98. Steiner G, Verschueren P, Van Hoovels L, et al. Classification of rheumatoid arthritis: is it time to revise the criteria? RMD Open. 2024; 10(2): e003851. doi: 10.1136/rmdopen-2023-003851.

99. Bossuyt X. Anticitrullinated protein antibodies: taking into account antibody levels improves interpretation. Ann Rheum Dis. 2017; 76(9): e33. doi: 10.1136/annrheumdis-2016-211039.

100. Tenstad HB, Nilsson AC, Dellgren CD, et al. Predictive values of anti-cyclic citrullinated peptide antibodies and rheumatoid factor in relation to serological aspects of the ACR/EULAR 2010 classification criteria for rheumatoid arthritis. Scand J Rheumatol. 2020; 49(1): 18-20. doi: 10.1080/03009742.2019.1609079.

101. Van Hoovels L, Vander Cruyssen B, Sieghart D, et al. Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. RMD Open. 2022; 8(1): e002099. doi: 10.1136/rmdopen-2021-002099.

102. Steiner G, Van Hoovels L, Csige D, et al. Should ACR/EULAR criteria be revised changing the RF and ACPA scores? Autoimmun Rev. 2024; 23(1): 103421. doi: 10.1016/j.autrev.2023.103421